Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice
暂无分享,去创建一个
G. Sobue | T. Takeuchi | H. Mochizuki | M. Neya | K. Sahashi | S. Matsuda | Y. Nagai | S. Ishigaki | E. Minakawa | Kazuhiro Maeta | S. Nagano | Yukako Oe | Akiko Takeda | Ding Xin | Mana Inoue | Tsuyoshi Fujihara